×
About 5,826 results

ALLMedicine™ Retinal Vein Occlusion Center

Research & Reviews  2,793 results

Hemoglobin C Trait Presenting with Bilateral Central Retinal Vein Occlusion.
https://doi.org/10.1097/ICB.0000000000001097
Retinal Cases & Brief Reports; Neuhouser AJ, Sanders RN et. al.

Nov 24th, 2020 - To report a case of bilateral sequential, CRVO in a man with newly diagnosed hemoglobin C trait. A 67-year-old man presented with a one-month history of declining visual acuity. He was diagnosed with left CRVO. Bilateral temporal retinal ischemia ...

Expression of the erythropoietin receptor in patients with proliferative diabetic retin...
https://doi.org/10.21037/apm-20-1898
Annals of Palliative Medicine; He G, Zhou J et. al.

Nov 23rd, 2020 - Proliferative diabetic retinopathy (PDR) is a leading cause of blindness. This study aimed to analyze the expression of the erythropoietin receptor (EpoR) in patients with PDR and its correlation with postoperative visual prognosis. Between May 20...

Comparison of the Effect of Intravitreal Conbercept and Ranibizumab on Aqueous Humor Cy...
https://doi.org/10.1089/jop.2020.0035
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics; Cui W, Sun XY et. al.

Nov 20th, 2020 - Purpose: To analyze changes in the levels of angiogenic and inflammatory cytokines following the administration of intravitreal conbercept (IVC) or intravitreal ranibizumab (IVR) in patients with macular edema (ME) due to central retinal vein occl...

Disorganisation of retinal inner layers is associated with reduced contrast sensitivity...
https://doi.org/10.1136/bjophthalmol-2020-317615
The British Journal of Ophthalmology; Wang J, Cui Y et. al.

Nov 11th, 2020 - To determine if disorganisation of retinal inner layers (DRIL) is associated with reduced contrast sensitivity (CS) in patients with retinal vein occlusion (RVO) with a history of macular oedema (ME). Prospective, observational cohort study. Patie...

Identification of microvascular and morphological alterations in eyes with central reti...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654769
PloS One; Hajdu D, Told R et. al.

Nov 10th, 2020 - To evaluate the characteristics and morphological alterations in central retinal ischemia caused by diabetic retinopathy (DR) or retinal vein occlusion (RVO) as seen in optical coherence tomography angiography (OCTA) and their relationship to visu...

see more →

Guidelines  1 results

Therapies for Macular Edema Associated with Branch Retinal Vein Occlusion: A Report by the A...
https://www.aaojournal.org/article/S0161-6420(17)30980-6/fulltext
Justis P. Ehlers

Aug 31st, 2017 - Current level I evidence suggests that intravitreal pharmacotherapy with anti-VEGF agents is effective and safe for ME secondary to BRVO. Prolonged delay in treatment is associated with less improvement in visual acuity (VA).

see more →

Drugs  4 results see all →

Clinicaltrials.gov  2,917 results

Hemoglobin C Trait Presenting with Bilateral Central Retinal Vein Occlusion.
https://doi.org/10.1097/ICB.0000000000001097
Retinal Cases & Brief Reports; Neuhouser AJ, Sanders RN et. al.

Nov 24th, 2020 - To report a case of bilateral sequential, CRVO in a man with newly diagnosed hemoglobin C trait. A 67-year-old man presented with a one-month history of declining visual acuity. He was diagnosed with left CRVO. Bilateral temporal retinal ischemia ...

Expression of the erythropoietin receptor in patients with proliferative diabetic retin...
https://doi.org/10.21037/apm-20-1898
Annals of Palliative Medicine; He G, Zhou J et. al.

Nov 23rd, 2020 - Proliferative diabetic retinopathy (PDR) is a leading cause of blindness. This study aimed to analyze the expression of the erythropoietin receptor (EpoR) in patients with PDR and its correlation with postoperative visual prognosis. Between May 20...

Comparison of the Effect of Intravitreal Conbercept and Ranibizumab on Aqueous Humor Cy...
https://doi.org/10.1089/jop.2020.0035
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics; Cui W, Sun XY et. al.

Nov 20th, 2020 - Purpose: To analyze changes in the levels of angiogenic and inflammatory cytokines following the administration of intravitreal conbercept (IVC) or intravitreal ranibizumab (IVR) in patients with macular edema (ME) due to central retinal vein occl...

Disorganisation of retinal inner layers is associated with reduced contrast sensitivity...
https://doi.org/10.1136/bjophthalmol-2020-317615
The British Journal of Ophthalmology; Wang J, Cui Y et. al.

Nov 11th, 2020 - To determine if disorganisation of retinal inner layers (DRIL) is associated with reduced contrast sensitivity (CS) in patients with retinal vein occlusion (RVO) with a history of macular oedema (ME). Prospective, observational cohort study. Patie...

Identification of microvascular and morphological alterations in eyes with central reti...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654769
PloS One; Hajdu D, Told R et. al.

Nov 10th, 2020 - To evaluate the characteristics and morphological alterations in central retinal ischemia caused by diabetic retinopathy (DR) or retinal vein occlusion (RVO) as seen in optical coherence tomography angiography (OCTA) and their relationship to visu...

see more →

News  109 results

Retinal Vein Occlusion Clinical Practice Guidelines (2019)
https://reference.medscape.com/viewarticle/917394

Sep 2nd, 2019 - In August 2019, the European Society of Retina Specialists (EURETINA) published clinical practice guidelines on the management of retinal vein occlusion (RVO).[1] Patients with suspected retinal vein occlusion (RVO) should undergo a full ophthalmo...

FDA OKs Aflibercept (Eylea) for Diabetic Retinopathy
https://www.medscape.com/viewarticle/913006

May 13th, 2019 - The US Food and Drug Administration (FDA) has approved aflibercept (Eylea, Regeneron) injection solution to treat all stages of diabetic retinopathy, the manufacturer has announced. Aflibercept, a vascular endothelial growth factor (VEGF) inhibito...

FDA Okays Aflibercept (Eylea) for Diabetic Retinopathy
https://www.staging.medscape.com/viewarticle/913006

May 13th, 2019 - The US Food and Drug Administration (FDA) has approved aflibercept (Eylea, Regeneron Pharmaceuticals) injection solution to treat all stages of diabetic retinopathy, the manufacturer has announced. Aflibercept, a vascular endothelial growth factor...

Anti-VEGF Tx Seems OK for Eye Disorders
https://www.medpagetoday.com/ophthalmology/generalophthalmology/71990

Mar 25th, 2018 - Intravitreal anti-VEGF treatments for neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion did not appear to increase the risk of systemic adverse events, particularly cardiovascular adverse e...

A Guide To Managing RVO: Ophthalmology Times
https://www.medpagetoday.com/ophthalmology/generalophthalmology/70255

Jan 2nd, 2018 - One expert discusses options for managing retinal vein occlusion over the long-term in patients with macular edema. A recent study reported that visual acuity did not improve when patients with diabetic macular edema received corticosteroid implan...

see more →

Patient Education  2 results see all →